Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Poseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018


Posted on: 29 Aug 18

Three presentations focus on Poseida’s clinical and preclinical CAR-T programs

SAN DIEGO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced that three abstracts detailing Poseida’s clinical and preclinical CAR-T programs have been selected for presentation at the 4th Annual CAR-TCR Summit, including a late breaking presentation with a clinical update on the Phase 1 study of Poseida’s P-BCMA-101 CAR-T therapy as a treatment for multiple myeloma.

Presentation Title: Update of P-BCMA-101-001 Phase 1 Clinical Trial: A Novel Stem Cell Memory CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
Presenter: Eric Ostertag, M.D., Ph.D., chief executive officer at Poseida
Track: Late Breaking Abstracts
Date and Time: 9:15 a.m. ET, Wednesday, Sept. 5, 2018

Presentation Title: A Stem Cell Memory CAR-T Therapy for Epithelial-Derived Solid Tumors
Presenter: Devon J. Shedlock, Ph.D., vice president of preclinical development at Poseida
Track: CAR-TCR Discovery
Date and Time: 2:35 p.m. ET, Thursday, Sept. 6, 2018

Presentation Title: Manufacture of Allogeneic “Universal Donor” CAR-T Therapies using piggyBac™ and Cas-CLOVER™ Gene Editing Technologies
Presenter: Burton Barnett, Ph.D., research scientist at Poseida
Track: CAR-TCR Manufacturing
Date and Time: 4:10 p.m. ET, Thursday, Sept. 6, 2018

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical stage biotechnology company translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida’s lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac™ DNA Modification System, TAL-CLOVER™ and Cas-CLOVER™ site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE). For more information, visit www.poseida.com.

Poseida has received grant funding from the California Institute for Regenerative Medicine to support the clinical development of P-BCMA-101.

Corporate Communications Contact:
Jason Spark
Canale Communications
619-849-6005
Jason@canalecomm.com

GlobeNewswire
globenewswire.com

Last updated on: 29/08/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.